JP2024509099A5 - - Google Patents

Info

Publication number
JP2024509099A5
JP2024509099A5 JP2023551711A JP2023551711A JP2024509099A5 JP 2024509099 A5 JP2024509099 A5 JP 2024509099A5 JP 2023551711 A JP2023551711 A JP 2023551711A JP 2023551711 A JP2023551711 A JP 2023551711A JP 2024509099 A5 JP2024509099 A5 JP 2024509099A5
Authority
JP
Japan
Prior art keywords
ala
val
cancer
compound according
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509099A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/051660 external-priority patent/WO2022180581A2/en
Publication of JP2024509099A publication Critical patent/JP2024509099A/ja
Publication of JP2024509099A5 publication Critical patent/JP2024509099A5/ja
Pending legal-status Critical Current

Links

JP2023551711A 2021-02-25 2022-02-25 抗her2抗体‐薬物コンジュゲートおよびその使用 Pending JP2024509099A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163153530P 2021-02-25 2021-02-25
US63/153,530 2021-02-25
PCT/IB2022/051660 WO2022180581A2 (en) 2021-02-25 2022-02-25 Anti-her2 antibody-drug conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2024509099A JP2024509099A (ja) 2024-02-29
JP2024509099A5 true JP2024509099A5 (cg-RX-API-DMAC7.html) 2025-02-06

Family

ID=80928968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551711A Pending JP2024509099A (ja) 2021-02-25 2022-02-25 抗her2抗体‐薬物コンジュゲートおよびその使用

Country Status (8)

Country Link
US (2) US12521444B2 (cg-RX-API-DMAC7.html)
EP (1) EP4297797A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024509099A (cg-RX-API-DMAC7.html)
KR (1) KR20230154892A (cg-RX-API-DMAC7.html)
CN (1) CN117320757A (cg-RX-API-DMAC7.html)
AU (1) AU2022228004A1 (cg-RX-API-DMAC7.html)
CA (1) CA3208591A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022180581A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12029736B2 (en) 2020-02-25 2024-07-09 Mediboston Limited Camptothecin derivatives and conjugates thereof
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
TW202430225A (zh) * 2022-12-29 2024-08-01 英屬開曼群島商百濟神州有限公司 B7h3抗體藥物共軛物
EP4688787A1 (en) * 2023-04-07 2026-02-11 Innovent Biologics (Suzhou) Co., Ltd. Antibody-drug conjugates of camptothecin derivatives and uses thereof
CN121969401A (zh) 2023-09-26 2026-05-01 信达生物制药(苏州)有限公司 靶向her3的抗体-药物偶联物
KR20260082305A (ko) * 2023-09-28 2026-06-04 포르비타 바이오로직스 인코포레이티드 Trop2를 표적화하는 항체-약물 접합체, 이의 제조 방법 및 용도
WO2025131054A1 (en) * 2023-12-22 2025-06-26 Innovent Biologics (Suzhou) Co., Ltd. Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
WO2025153054A1 (en) * 2024-01-18 2025-07-24 Nona Biosciences (Suzhou) Co., Ltd. Camptothecin analogues, conjugates and methods of use
WO2025195402A1 (zh) * 2024-03-20 2025-09-25 福佑泰生物制药公司 靶向trop2的抗体-药物偶联物治疗癌症的方法
WO2026046180A1 (en) * 2024-08-27 2026-03-05 Suzhou Bioreinno Biotechnology Limited Company Compounds, conjugates and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5049668A (en) 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991004260A2 (en) 1989-09-15 1991-04-04 Research Triangle Institute 10,11-methylenedioxy-20(rs)-camptothecin and 10,11-methylenedioxy-20(s)-camptothecin analogs
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP2684104B2 (ja) 1990-02-09 1997-12-03 株式会社ヤクルト本社 新規なカンプトテシン誘導体
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DK0547165T3 (da) 1990-09-28 2000-03-27 Smithkline Beecham Corp Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU2394392A (en) 1991-12-10 1993-07-19 Smithkline Beecham Corporation Treatment of colorectal cancer
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1534674A4 (en) 2002-08-02 2007-11-28 Immunogen Inc CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE
EP1542723B1 (en) 2002-08-16 2011-02-23 ImmunoGen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN100406460C (zh) 2003-11-10 2008-07-30 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
CN100354279C (zh) 2004-06-04 2007-12-12 中国科学院上海药物研究所 喜树碱的新型结构衍生物、制备方法和用途
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
WO2007095389A2 (en) 2006-02-17 2007-08-23 Novacea, Inc. Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
CN103003843B (zh) 2010-05-28 2016-08-03 高通股份有限公司 用于跟踪具有动态变化部分的目标的数据集创建
ES2371171B1 (es) 2010-06-08 2012-11-16 Consejo Superior De Investigaciones Científicas (Csic) Derivados de camptotecina como agentes antitumorales.
ES2373172B1 (es) 2010-07-16 2012-12-10 Consejo Superior De Investigaciones Científicas (Csic) Proceso de obtención de derivados solubles en agua de 20 (s) camptotecina como agentes antitumorales.
CN102477042A (zh) 2010-11-26 2012-05-30 复旦大学 10-羟基喜树碱衍生物及其制备方法和用途
US9511150B2 (en) * 2011-07-19 2016-12-06 CellMosaic, Inc. Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
CN103289461B (zh) 2013-07-01 2016-05-04 厦门大学 喜树碱及其衍生物作为防污剂的应用
US11185594B2 (en) * 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
US20180018682A1 (en) 2015-02-06 2018-01-18 University Of Technology Sydney Devices, Frameworks and Methodologies Configured to Enable Automated Monitoring and Analysis of Dwell Time
WO2018066626A1 (ja) * 2016-10-07 2018-04-12 第一三共株式会社 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
CN109106951A (zh) 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
CN111936169A (zh) 2018-04-06 2020-11-13 西雅图遗传学公司 喜树碱肽缀合物
US20210163964A1 (en) 2018-04-06 2021-06-03 University Of Florida Research Foundation, Incorporated Engineered streptomyces albus strains
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
CN109467563B (zh) 2018-06-08 2021-08-03 浙江大学 一种喜树碱衍生物及其在制备抗炎症药物中的应用
RS64961B1 (sr) * 2019-04-26 2024-01-31 Immunogen Inc Derivati kamptotecina
US12029736B2 (en) 2020-02-25 2024-07-09 Mediboston Limited Camptothecin derivatives and conjugates thereof
PH12022500032A1 (en) * 2020-06-19 2024-02-26 Hangzhou Dac Biotech Co Ltd Conjugates of a cell-binding molecule with camptothecin analogs

Similar Documents

Publication Publication Date Title
JP2024535637A5 (cg-RX-API-DMAC7.html)
CN112839683B (zh) 含有标记部-抗人抗体Fab片段复合物的药物组合物
FI4067387T3 (fi) Bispesifinen anti-pd-1-anti-vegfa -vasta-aine, farmaseuttinen koostumus ja sen käyttö
HRP20250345T1 (hr) Konjugati antitijelo - lijek derivata cikličnih dinukleotida
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2020506971A5 (cg-RX-API-DMAC7.html)
JP2019533475A5 (cg-RX-API-DMAC7.html)
JP2022542165A5 (cg-RX-API-DMAC7.html)
AU2022228004A1 (en) Anti-her2 antibody-drug conjugates and uses thereof
JP2022530404A5 (cg-RX-API-DMAC7.html)
JP2004529963A5 (cg-RX-API-DMAC7.html)
JPWO2021177438A5 (cg-RX-API-DMAC7.html)
JP2022553702A5 (cg-RX-API-DMAC7.html)
JP2024542192A5 (cg-RX-API-DMAC7.html)
JP2024536881A5 (cg-RX-API-DMAC7.html)
JP2024088768A5 (cg-RX-API-DMAC7.html)
JP2025503493A5 (cg-RX-API-DMAC7.html)
KR20250044409A (ko) 부위 특이적 변형이 있는 항체를 제조하는 방법
JP2024501453A5 (cg-RX-API-DMAC7.html)
CN109125736B (zh) 非天然鹅膏毒肽类抗体偶联物
JP2023552790A5 (cg-RX-API-DMAC7.html)
RU2015141408A (ru) Новый опухолевый биомаркер
JP2023552792A5 (cg-RX-API-DMAC7.html)
JP2023552791A5 (cg-RX-API-DMAC7.html)
JP2025508779A5 (cg-RX-API-DMAC7.html)